Take the Money and Run Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jorj X Mckie who wrote (6612)	6/28/2002 9:25:33 AM
From: SusieQ1065	Read Replies (1) of 17639

Biotech's getting pump today.. 09:17 ET CEPH Cephalon: Actiq growing faster than expected-- Piper Jaffray (44.35) USB Piper Jaffray says that demand for CEPH's Actiq pain treatment appears to be growing more rapidly than expected, and that Provigil sales appear to be tracking to meet or beat their Q2 sales forecast; raises 2002 est to $1.07 from $1.05 and 2003 to $1.50 from $1.45, and raises price target to $90 from $87. 08:55 ET UBS on prescription drug bill UBS Warburg believes that the mkt should view the news that the House passed a prescription drug bill as marginally positive; firm thinks that this bill faces an uphill battle in the Senate, but that eventual passage of a prescription drug benefit will be a positive for the industry as it will help to alleviate some of the pressure on drug prices.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next